
News
- Home
- >
- News
Latest news
-
21 September 2023BTG Pharmaceuticals, a SERB company, to present data on ricin antidote development programme at the North American Congress of Clinical ToxicologySERB will present in vivo data for a polyclonal antibody in development as an antidote for ricin poisoning, on the first day of the upcoming NACCT in Montreal.
-
13 July 2023SERB Pharmaceuticals acquires Vistogard® and Xuriden® from Wellstat TherapeuticsWest Conshohocken, PA, 13 July 2023: SERB Pharmaceuticals, a global specialty pharmaceutical company, announced today that it has acquired two life-saving medicines, Vistogard® (uridine triacetate) and Xuriden® (uridine triacetate), from Wellstat Therapeutics. Both medicines are commercially available in the US and currently distributed across Europe on a named patient or compassionate use basis. Jeremie Urbain, […]
-
22 June 2023BTG Pharmaceuticals Statement on NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Recommendation for Use of Glucarpidase (Voraxaze®) and MTXPK.orgWest Conshohocken, PA, 22 June 2023: BTG Pharmaceuticals, a SERB company, highlights the recent updates to the National Comprehensive Cancer Network (NCCN) Guidelines for Acute Lymphoblastic Leukemia, B-Cell Lymphomas, Pediatric Acute Lymphoblastic Leukemia, and Pediatric Aggressive Mature B-Cell Lymphomas. i-iv The updated guidelines: “The updated guidelines will help ensure that healthcare professionals understand the current […]
News archive
Date
Title